From the departments of Rheumatology, Radiology, and Clinical Epidemiology, Leiden University Medical Center (LUMC), Leiden, the Netherlands.
W. Damman, MD, Department of Rheumatology, LUMC; R. Liu, MD, Department of Rheumatology, LUMC; F.P. Kroon, MD, Department of Rheumatology, LUMC; M. Reijnierse, MD, PhD, Department of Radiology, LUMC; T.W. Huizinga, MD, PhD, Department of Rheumatology, LUMC; F.R. Rosendaal, MD, PhD, Department of Clinical Epidemiology, LUMC; M. Kloppenburg, MD, PhD, Department of Rheumatology, and Department of Clinical Epidemiology, LUMC.
J Rheumatol. 2017 Nov;44(11):1659-1666. doi: 10.3899/jrheum.170208. Epub 2017 Sep 15.
Because the association and its clinical relevance between comorbidities and primary hand osteoarthritis (OA) disease burden is unclear, we studied this in patients with hand OA from our Hand OSTeoArthritis in Secondary care (HOSTAS) cohort.
Cross-sectional data from the HOSTAS study were used, including consecutive patients with primary hand OA. Nineteen comorbidities were assessed: 18 self-reported (modified Charlson index and osteoporosis) and obesity (body mass index ≥ 30 kg/m). Mean differences were estimated between patients with versus without comorbidities, adjusted for age and sex: for general disease burden [health-related quality of life (HRQOL), Medical Outcomes Study Short Form-36 physical component scale (0-100)] and disease-specific burden [self-reported hand function (0-36), pain (0-20; Australian/Canadian Hand OA Index), and tender joint count (TJC, 0-30)]. Differences above a minimal clinically important improvement/difference were considered clinically relevant.
The study included 538 patients (mean age 61 yrs, 86% women, 88% fulfilled American College of Rheumatology classification criteria). Mean (SD) HRQOL, function, pain, and TJC were 44.7 (8), 15.6 (9), 9.3 (4), and 4.8 (5), respectively. Any comorbidity was present in 54% (287/531) of patients and this was unfavorable [adjusted mean difference presence/absence any comorbidity (95% CI): HRQOL -4.4 (-5.8 to -3.0), function 1.9 (0.4-3.3), pain 1.4 (0.6-2.1), TJC 1.3 (0.4-2.2)]. Number of comorbidities and both musculoskeletal (e.g., connective tissue disease) and nonmusculoskeletal comorbidities (e.g., pulmonary and cardiovascular disease) were associated with disease burden. Associations with HRQOL and function were clinically relevant.
Comorbidities showed clinically relevant associations with disease burden. Therefore, the role of comorbidities in hand OA should be considered when interpreting disease outcomes and in patient management.
由于合并症与原发性手部骨关节炎(OA)疾病负担之间的关联及其临床相关性尚不清楚,我们在来自我们的 HAND OSTeoArthritis IN SECONDARY care(HOSTAS)队列的手部 OA 患者中对此进行了研究。
使用 HOSTAS 研究的横断面数据,包括连续的原发性手部 OA 患者。评估了 19 种合并症:18 种自我报告的(改良 Charlson 指数和骨质疏松症)和肥胖症(体重指数≥30kg/m²)。在调整年龄和性别后,估计了有合并症和无合并症患者之间的平均值差异:一般疾病负担[健康相关生活质量(HRQOL),医疗结果研究 36 项简短形式量表(0-100)]和疾病特异性负担[自我报告的手部功能(0-36),疼痛(0-20;澳大利亚/加拿大手部 OA 指数),和压痛关节计数(TJC,0-30)]。超过最小临床重要改善/差异的差异被认为具有临床相关性。
该研究纳入了 538 名患者(平均年龄 61 岁,86%为女性,88%符合美国风湿病学会分类标准)。HRQOL、功能、疼痛和 TJC 的平均值(标准差)分别为 44.7(8)、15.6(9)、9.3(4)和 4.8(5)。531 名患者中有 54%(287 名)存在任何合并症,且这种情况不利[调整后的有/无任何合并症的平均差异(95%CI):HRQOL-4.4(-5.8 至-3.0),功能 1.9(0.4-3.3),疼痛 1.4(0.6-2.1),TJC 1.3(0.4-2.2)]。合并症的数量以及肌肉骨骼(例如结缔组织疾病)和非肌肉骨骼合并症(例如肺部和心血管疾病)与疾病负担相关。与 HRQOL 和功能的关联具有临床相关性。
合并症与疾病负担具有临床相关性。因此,在解释手部 OA 的疾病结局和患者管理时,应考虑合并症的作用。